Author = Fatemeh Kazemi-Lomedasht
Number of Articles: 5
1. Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate

Volume 25, Issue 3, March 2022, Pages 313-319

Akbar Oghalaei; Feriedon Mahbudi; Fatemeh Rahimi Jamnani; Somayeh Piri-Gavgani; Fatemeh Kazemi-Lomedasht; Aida Hassanzadeh-Eskafi; Delavar Shahbazzadeh; Ahmad Adeli; Yeganeh Talebkhan; Mahdi Behdani


2. In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin

Volume 25, Issue 1, January 2022, Pages 27-31

Mohammad Hosseininejad-Chafi; Ehsan Alirahimi; Behzad Ramezani; Akbar Oghalaei; Nazli Sotoudeh; Hajarsadat Ghaderi; Fatemeh Kazemi-Lomedasht; Mahdi Habibi-Anbouhi; Reza Moazzami; Mahdi Behdani


3. Development of camelid monoclonal nanobody against SLC39A6 zinc transporter protein

Volume 24, Issue 12, December 2021, Pages 1726-1733

Hajarsadat Ghaderi; Zahra Noormohammadi; Mahdi Habibi-Anbouhi; Fatemeh Kazemi-Lomedasht; Mahdi Behdani


4. Developing and characterizing a single-domain antibody (nanobody) against human cytotoxic T-lymphocyte-associated protein 4 (hCTLA-4)

Volume 24, Issue 9, September 2021, Pages 1264-1271

Nazli Sotoudeh; Zahra Noormohammadi; Mahdi Habibi-Anbouhi; Fatemeh Kazemi-Lomedasht; Mahdi Behdani


5. Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function

Volume 21, Issue 3, March 2018, Pages 260-266

Fatemeh Kazemi-Lomedasht; serge muyldermans; Mahdi Habibi-Anbouhi; Mahdi Behdani